The effect of recombinant human interferon alpha B/D compared to interferon alpha 2b on SIV infection in rhesus macaques.
The model of simian immunodeficiency virus (SIV) infection in rhesus macaques was used to evaluate the effects of recombinant human interferon alpha, Hu IFN-alpha 2b and Hu IFN-gamma B,D, at two doses. Administration began 1 day prior to infection and was continued for 90 days postinfection. Both interferons suppressed SIV antigenemia during the treatment period. Following treatment animals were monitored for 4 years for rate of disease progression. Neither IFN prolonged the asymptomatic period or survival.
Schellekens
H
H
Diagnostic Centre SSDZ, Department of Infectious Diseases and Immunology, The Netherlands.
Niphuis
H
H
Buijs
L
L
Douw van der Krap
P
P
Hochkeppel
H K
HK
Heeney
J L
JL
D000818:Animals; D000956:Antigens, Viral / Q000097:blood; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D018791:CD4 Lymphocyte Count; D015683:Gene Products, gag / Q000097:blood / Q000276:immunology; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology*; D008253:Macaca mulatta; D019798:Neopterin; D011994:Recombinant Proteins; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy* / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000276:immunology; D013997:Time Factors
D000956:Antigens, Viral; C066594:Gag protein p27, Simian immunodeficiency virus; D015683:Gene Products, gag; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D001708:Biopterins; D019798:Neopterin